Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multi-center, Open-label Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) Who Have Failed Dasatinib or Nilotinib or Ph+ Acute Lymphoblastic Leukemia (ALL) Who Have Failed Prior Tyrosine Kinase Inhibitors (TKIs)

NCT01667133 is registered in ClinicalTrials.gov with Ariad Pharmaceuticals as lead sponsor.

NCT NCT01667133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01667133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multi-center, Open-label Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) Who Have Failed Dasatinib or Nilotinib or Ph+ Acute Lymphoblastic Leukemia (ALL) Who Have Failed Prior Tyrosine Kinase Inhibitors (TKIs)
Lead sponsor
Ariad Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2012
Completion date
August 2, 2018
Enrollment
35 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia (cml), philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all)